Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03187535

Effect of TEAS on PONV After Spinal Surgery

The proposed research will utilize electroacupuncture, a type of needleless acupuncture that uses electrostimulation, in a randomized, double blind study, to evaluate the incidence of post-operative nausea and vomiting (PONV) in patients undergoing spinal surgeries with the transcutaneous electrical acupoint stimulation (TEAS) compared to patients without TEAS.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

The rates of PONV will be evaluated over the first 24 hours after surgery, opioid consumption in units of morphine equivalence, and any adverse side effects will be recorded. Subjects who are included in the research will be randomly assigned to one of two groups - one group is the control group, receiving no TEAS, and the other group receiving TEAS. An anesthesiologist trained in acupuncture will utilize the Excel Pointer to locate the specific acupoints previously identified as associated with prevention PONV. Anesthesiologist will place electrocardiogram (ECG) pads at the identified acupoints prior to surgery. Subjects will be connected to the ES-130 (electro-therapy) device upon entering the operating room. Prior to the surgical closure, the unblinded researcher will initiate delivery of TEAS, or not, according to study protocol based on the randomization group of the participant. The anesthesiologist will not know the group assignment. At the end of surgery, the subject will be disconnected from the ES-130 and the ECG pads will be carefully removed. Researchers will follow up with the subject in recovery regarding any occurrence and severity of PONV, adverse events, and verbal pain scores, until 24 hours after end of surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients , 18 or older
  • American Society of Anesthesiologists (ASA) classification I or II or III
  • Undergoing elective spinal surgery expected to last no more than four hours (from induction of anesthesia to extubation).
  • Capable and willing to consent

Exclusion criteria

  • Neuraxial (intrathecal or epidural) block
  • Significant ongoing history of vestibular disease or dizziness
  • Nausea or vomiting within 24 hours prior to surgery, use of antiemetic or emetogenic drugs within 3 days of surgery
  • Documented alcohol or substance abuse within 3 months before the surgery
  • Limb abnormalities such as burn and amputation.
  • Poorly controlled diabetes mellitus (fasting plasma glucose >126 mg/dL or <70 mg/dL)
  • Implantation of metal/electrical devices, such as nerve stimulator, cardiac pacemaker, cardioverter, defibrillator and internal hearing aids
  • Rash, local infection, keloid, any dermatologic condition that could interfere with the acupoint stimulation area
  • Documented alcohol or substance abuse within 3 months before surgery
  • Presence of clinically diagnosed major psychiatric condition such as bipolar disorder, uncontrolled major depression, or schizophrenia
  • Chemotherapy or radiation therapy within 7 days before surgery
  • Investigational product use within 3 months prior surgery
  • Any condition, which in the opinion of the investigator would make subject ineligible for participation in the study (history of unstable cardiovascular, pulmonary, renal, hepatic, seizures)
  • Special population (prisoners, pregnant and lactating women)

Treatment and study plan

TEAS via ES-130

Device

Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.

No TEAS

Other

No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.

Primary outcomes

  1. incidence of PONV

    Time frame: up to 24 hours after surgery

    measure the incidence of PONV in spinal surgery

  2. severity of PONV

    Time frame: up to 24 hours after surgery

    use Verbal Rating Scale (VRS) score (0-10) to rate nausea

Secondary outcomes

  1. Time to first nausea/vomiting rescue medication

    Time frame: within 2 and 24 hours after surgery

    Time until subject requests rescue anti-emetic therapy

  2. opioid consumption (units of morphine equivalence)

    Time frame: 2 and 24 hours after surgery

    compare the opioid consumption after surgery in units of morphine

  3. incidence of adverse events

    Time frame: 24 hours after surgery

    compare incidence of adverse events between groups

Study contacts

Contact information is provided by the study sponsor or research team.

Alberto Uribe, MD

CONTACT

[email protected]

614-293-3559

Juan Fiorda, MD, PhD

CONTACT

[email protected]

614-293-3559

Sponsors and collaborators

Lead sponsor

Jyoti Pandya

Other

Registry information

Official study title

The Effect of Transcutaneous Electric Acupoint Stimulation on Post-operative Nausea and Vomiting After Spinal Surgery

Important dates

Study start
2018
Primary completion
2027
Study completion
2027
First posted
Jun 15, 2017
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.